Inovio's Losses Widen Amidst Going Concern Doubts

Ticker: INO · Form: 10-Q · Filed: Nov 10, 2025 · CIK: 1055726

Inovio Pharmaceuticals, INC. 10-Q Filing Summary
FieldDetail
CompanyInovio Pharmaceuticals, INC. (INO)
Form Type10-Q
Filed DateNov 10, 2025
Risk Levelhigh
Pages15
Reading Time19 min
Key Dollar Amounts$0.001
Sentimentbearish

Sentiment: bearish

Topics: Biotechnology, DNA Medicines, Going Concern, Net Loss, Cash Burn, Clinical Stage, HPV

TL;DR

**INOVIO is burning cash fast with a 'going concern' warning, making it a high-risk bet despite R&D cuts.**

AI Summary

INOVIO PHARMACEUTICALS, INC. reported a significant increase in net loss for the three and nine months ended September 30, 2025, reaching $45.5 million and $88.7 million, respectively, compared to $25.2 million and $87.9 million for the same periods in 2024. This substantial increase in loss was primarily driven by a $20.7 million change in the fair value of common stock warrant liabilities for the nine months ended September 30, 2025, which was not present in 2024. Revenue from collaborative arrangements decreased to $65,343 for the nine months ended September 30, 2025, from $100,762 in 2024. Research and development expenses decreased by 30% to $43.9 million for the nine months ended September 30, 2025, from $62.7 million in 2024, while general and administrative expenses also saw a reduction to $25.5 million from $29.4 million. The company's cash and cash equivalents significantly declined to $36.6 million as of September 30, 2025, from $65.8 million at December 31, 2024, and it reported a working capital deficit of $(14.6) million. A substantial doubt exists regarding INOVIO's ability to continue as a going concern, as it does not have sufficient working capital to fund planned operations for the next twelve months.

Why It Matters

INOVIO's deepening losses and explicit 'going concern' warning signal significant financial instability, directly impacting investor confidence and potentially the company's ability to fund critical DNA medicine development. For employees, this raises job security concerns and could hinder talent acquisition. Customers and the broader market, particularly those awaiting treatments like INO-3107 for RRP, face uncertainty regarding product timelines and availability. In a highly competitive biotech landscape, INOVIO's financial struggles could allow rivals with stronger balance sheets to gain a significant advantage in novel DNA medicine development.

Risk Assessment

Risk Level: high — INOVIO explicitly states, "We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern." The company's working capital deficit was $(14.6) million as of September 30, 2025, and cash and cash equivalents plummeted from $65.8 million at December 31, 2024, to $36.6 million at September 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider divesting, given the explicit 'going concern' warning and significant cash burn. New investors should avoid INOVIO until a clear, funded path to profitability or substantial new capital infusion is demonstrated.

Financial Highlights

debt To Equity
N/A
revenue
$65,343
operating Margin
N/A
total Assets
$69.4M
total Debt
$77.1M
net Income
$-88.7M
eps
$-2.12
gross Margin
N/A
cash Position
$36.6M
revenue Growth
-35.1%

Revenue Breakdown

SegmentRevenueGrowth
Revenue from collaborative arrangement$65,343-35.1%

Key Numbers

Key Players & Entities

FAQ

What is INOVIO Pharmaceuticals' current financial liquidity position?

INOVIO Pharmaceuticals reported cash and cash equivalents of $36,567,420 as of September 30, 2025, a significant decrease from $65,813,297 at December 31, 2024. The company also has a working capital deficit of $(14.6) million, indicating insufficient funds for its planned operations over the next twelve months.

Why did INOVIO's net loss increase in Q3 2025?

INOVIO's net loss for the three months ended September 30, 2025, increased to $45,496,672 from $25,165,478 in the same period of 2024. A primary driver for this increase was a $22,515,730 change in the fair value of common stock warrant liabilities, which was not present in the prior year.

What are the key risks highlighted in INOVIO's 10-Q filing?

The 10-Q highlights several key risks, including significant accumulated losses of $1.8 billion, limited revenue sources, the need for substantial additional capital, and a 'going concern' warning due to insufficient working capital for the next twelve months. Regulatory approval for its drug-device combination products and intense competition are also major concerns.

What is the status of INOVIO's lead product candidate, INO-3107?

INOVIO's lead candidate, INO-3107, is for the treatment of recurrent respiratory papillomatosis (RRP). In its completed Phase 1/2 clinical trial, 81.3% of patients experienced a reduction in surgical interventions in the year following administration of INO-3107, compared to the year prior to treatment.

How have INOVIO's research and development expenses changed?

Research and development expenses for the nine months ended September 30, 2025, decreased to $43,945,638, a 30% reduction from $62,734,891 for the same period in 2024. This reduction in R&D spending could reflect strategic pipeline adjustments or financial constraints.

What is the significance of the 'going concern' warning for INOVIO investors?

The 'going concern' warning signifies that INOVIO's management has substantial doubt about the company's ability to continue operating for the next twelve months without securing additional funding. For investors, this indicates a high risk of financial distress, potential bankruptcy, or significant dilution through future capital raises.

Does INOVIO have any ongoing collaborations for its DNA medicines?

Yes, INOVIO has collaborations with several entities, including Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, Coherus Biosciences, DARPA, NIH, NIAID, and Regeneron Pharmaceuticals. For example, ApolloBio Corporation continues a Phase 3 clinical trial of an HPV-related cervical HSIL candidate in China.

What is INOVIO's strategy for developing its DNA medicines?

INOVIO's strategy focuses on developing and commercializing DNA medicines using proprietary technology to design DNA plasmids and its investigational CELLECTRA devices for delivery. The platform aims to teach the body to produce its own disease-fighting tools without chemical adjuvants, lipid nanoparticles, or viral vectors.

How has INOVIO's common stock outstanding changed?

The number of shares outstanding of INOVIO's Common Stock increased significantly to 53,571,675 as of November 7, 2025, from 36,099,991 as of December 31, 2024. This increase is primarily due to the issuance of common stock for cash and the exercise of warrants and pre-funded warrants.

What impact do regulatory approvals have on INOVIO's business?

Regulatory approvals are critical for INOVIO, as its success depends on obtaining FDA approval for its proprietary devices and DNA medicine candidates. The complexity of developing drug-device combination products, like its CELLECTRA delivery devices, may require additional time and could delay commercialization if not approved.

Risk Factors

Industry Context

The biotechnology sector, particularly companies focused on vaccine development, is highly competitive and capital-intensive. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies. Companies often rely on partnerships and significant R&D investment, facing challenges in revenue generation until products reach the market.

Regulatory Implications

As a biotechnology company, INOVIO is subject to stringent regulatory oversight from bodies like the FDA. Delays or failures in clinical trials, manufacturing issues, or non-compliance with Good Manufacturing Practices (GMP) can lead to significant setbacks, financial penalties, and reputational damage.

What Investors Should Do

  1. Monitor cash burn rate and future financing activities.
  2. Evaluate the impact of reduced R&D spending.
  3. Assess the volatility of warrant liabilities.
  4. Consider the implications of share dilution.

Key Dates

Glossary

Common stock warrant liabilities
Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. Their value fluctuates with the stock price and can result in gains or losses for the company. (A significant increase in the fair value of these liabilities contributed substantially to the company's net loss in the nine months ended September 30, 2025.)
Working capital deficit
Occurs when a company's current liabilities exceed its current assets, indicating a potential inability to meet short-term obligations. (INOVIO has a working capital deficit of $(14.6) million, raising substantial doubt about its ability to continue as a going concern.)
Going concern
An accounting assumption that a business will continue to operate for the foreseeable future, typically at least the next 12 months. If substantial doubt exists, it must be disclosed. (The company's financial condition has led to substantial doubt regarding its ability to continue as a going concern.)
Accumulated deficit
The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total historical losses that have not been offset by profits. (INOVIO has an accumulated deficit of $1.8 billion, highlighting its long-standing unprofitability.)
Dilution
The reduction in the ownership percentage of a stock resulting from the issuance of new shares. This can decrease earnings per share and voting power for existing shareholders. (The increase in common shares outstanding indicates potential dilution for current investors.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, INOVIO reported a wider net loss for the three months ended September 30, 2025 ($45.5M vs $25.2M), though the nine-month net loss remained relatively stable ($88.7M vs $87.9M). Revenue from collaborative arrangements decreased, while operating expenses, particularly R&D, were significantly reduced. A major new risk factor is the substantial increase in common stock warrant liabilities, which heavily impacted the current period's net loss. The company's cash position has deteriorated significantly, and its working capital deficit has worsened, intensifying going concern risks.

Filing Stats: 4,648 words · 19 min read · ~15 pages · Grade level 15.9 · Accepted 2025-11-10 16:01:12

Key Financial Figures

Filing Documents

Financial Information

Part I. Financial Information 1

Financial Statements

Item 1. Financial Statements 1 a) Condensed Consolidated Balance Sheets 2 b) Condensed Consolidated Statements of Operations 3 c) Condensed Consolidated Statements of Comprehensive Loss 4 d) Condensed Consolidated Statements of Stockholders' Equity 5 e) Condensed Consolidated Statements of Cash Flows 7 f) Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 26

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 32

Controls and Procedures

Item 4. Controls and Procedures 32

Other Information

Part II. Other Information 34

Legal Proceedings

Item 1. Legal Proceedings 34

Risk Factors

Item 1A. Risk Factors 34

Other Information

Item 5. Other Information 62

Exhibits

Item 6. Exhibits 62

Signatures

Signatures 64 SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Item 1A. Risk Factors herein. These risk factors include, but are not limited to, the following: We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable. We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology. We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain. We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern. If we are unable to obtain FDA approval of our proprietary devices and DNA medicine candidates, we will not be able to commercialize them in the United States. In particular, because our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory agencies do not provide marketing authorization for our CELLECTRA delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device. DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA delivery devices are a novel approach to administering medicines, and negative perception

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements 1 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 36,567,420 $ 65,813,297 Short-term investments 14,235,770 28,300,232 Accounts receivable from affiliated entity 978,590 1,199,056 Prepaid expenses and other current assets 3,398,534 2,517,465 Total current assets 55,180,314 97,830,050 Fixed assets, net 2,740,356 3,659,818 Investments in affiliated entity 2,495,730 1,613,844 Operating lease right-of-use assets 6,956,780 8,113,840 Other assets 2,012,476 1,979,654 Total assets $ 69,385,656 $ 113,197,206 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 15,323,520 $ 16,200,013 Accounts payable and accrued expenses due to affiliated entity 379,721 1,351,163 Accrued clinical trial expenses 955,970 2,021,860 Common stock warrant liabilities 50,384,043 13,255,188 Operating lease liability 2,738,490 2,497,360 Grant funding liability from affiliated entity 42,152 — Total current liabilities 69,823,896 35,325,584 Operating lease liability, net of current portion 7,281,737 9,367,827 Total liabilities 77,105,633 44,693,411 Stockholders' equity: Preferred stock — — Common stock 53,572 36,099 Additional paid-in capital 1,811,803,850 1,799,362,625 Accumulated deficit ( 1,818,930,043 ) ( 1,730,219,262 ) Accumulated other comprehensive loss ( 647,356 ) ( 675,667 ) Total Inovio Pharmaceuticals, Inc. stockholders' equity ( 7,719,977 ) 68,503,795 Total liabilities and stockholders' equity $ 69,385,656 $ 113,197,206 See accompanying notes to unaudited condensed consolidated financial statements. 2 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues: Revenue from collaborative arrangement $ — $ — $ 65,343 $ 100,7

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing